COSENTYX (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
COSENTYX
Date registered
Evaluation commenced
Decision date
Approval time
146 working days (255)
Active ingredients
secukinumab
Registration type
EOI
Indication
COSENTYX (powder for injection; solution for injection) is now also indicated for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or MRI change, who have had an inadequate response to, or are intolerant to, NSAIDs.